期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 25, 期 3, 页码 287-296出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0b013e32835fd8d5
关键词
ankylosing spondylitis; axial spondyloarthritis; biologic therapy; psoriatic arthritis; spondyloarthritis
类别
资金
- Abbvie
- Amgen
- BiogenIdec
- Bristol Myers
- Celgene
- Genentech
- Janssen
- Lilly
- Merck
- Novartis
- Pfizer
- UCB
Purpose of review There have been numerous recent advances in our understanding about the epidemiology, pathophysiology, classification, assessment, and emerging treatments and treatment paradigms of psoriatic arthritis (PsA) and spondyloarthritis (SpA). This review provides an update on classification, assessment approaches, and treatments for these conditions. This is timely because it is becoming clear that the prevalence of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of SpA may be present in 1-2% of the general population, more prevalent than rheumatoid arthritis (RA). Recent findings There are new classification criteria of axial and peripheral SpA as well as the CASPAR criteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new measures for the heterogeneous clinical domains of PsA, studies of biologic treatments of axial and peripheral SpA, and new drugs beyond anti-tumor necrosis factors for PsA and SpA. Summary New criteria, assessment tools, and therapies will aid research, diagnosis, and timely and targeted treatment to quantitated outcomes for PsA and SpA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据